Facing the complex, ever-changing and highly anticipated year of 2022

Elixir Clinical Research is on the way to chase ideals

Forging ahead

Constantly arriving and departing

Ending with a "highly-productive" half-year

Creating a strong momentum for the start of second half of the year

Company Milestones

01

Announcement | Dr. Jie Chen joins Elixir Clinical Research as Chief Scientific Officer

Elixir Clinical Research recently announced that Dr. Jie Chen, with 26 years of biopharmaceutical R&D experience, has joined the company as Chief Scientific Officer. Dr. Jie Chen will be responsible for the expansion and management of the company's Biostatistics and Computational Science Department after he joins Elixir Clinical Research. Science-led and innovation-empowered approaches will be used to build the Biostatistics and Computational Science Department into a leading team in the CRO industry.

02

Announcement | Jerry Weaver joins Elixir Clinical Research as Vice President and Head of U.S. Operations

In May, Elixir Clinical Research announced that Mr. Jerry Weaver, with 30 years of biopharmaceutical R&D experience, has joined the company as Vice President and Head of U.S. Operations. Mr. Jerry Weaver will be responsible for the expansion and operations of the company's business in the United States after he joins Elixir Clinical Research. Technology-led science and talent-supported development along with the joining of Mr. Jerry Weaver will enable Elixir Clinical Research to enter into a new chapter for the deployment of globalized R&D and the construction of international multicenter clinical service capability.

03

Elixir Clinical Research completed A round financing worth of $52 million, which is jointly invested by LYFE Capital, Sinovation Ventures and Chow Tai Fook

In April, Elixir Clinical Research announced that it has recently completed A round financing. This round of financing is jointly invested by LYFE Capital, Sinovation Ventures and Chow Tai Fook. Mr. Liedong Xu, General Manager of Elixir Clinical Research, said that at the national level, multiple important policies that encourage medical innovations, will further advance the continuous progress in CRO industry and achieve high-quality and high-efficacy innovative development. He believes that this round of financing will further enhance Elixir Clinical Research's clinical informatization management level and data value mining ability, enhance the team's professional service ability and establish an international service team to create higher value for clients.

Meeting Highlights

01

Elixir Clinical Research, a key biopharmaceutical enterprise in Minhang District, was invited to participate in district industry gatherings

On February 22, the Industrial Cluster CPC Building Gatherings (Biomedical topic) under the theme of "Leading a New Journey, Gathering Wisdom and New Dynamics" in Minhang District was held in the Greater neoBay CPC-Masses Service Center. Elixir Clinical Research was invited to participate in this event as a key biopharmaceutical company in Minhang District. At the event, the Secretary of Minhang District Committee and the Director of District Science and Technology Committee visited the booth of Elixir Clinical Research, learned in detail about Elixir Clinical Research's current production, operation, innovation and development, and expressed recognition and strong support for the company's continuous service and business innovation with digital technology, which actively empowers clinical study management and operation.

02

Event Review | Elixir Clinical Research attended the 7th CMAC Annual Conference

From July 7-10, China Innovative Medicine (Device) Medical Conference ＆ the 7th CMAC Annual Conference were successfully held in Hangzhou. Dr. Jie Chen, Chief Scientific Officer of Elixir Clinical Research and Dr. Yuji Feng, Associate General Manager of R&D and Head of Real-World Studies, were invited to attend and gave presentations on "Real-World Studies - Latest Progress, Challenges and Future Directions" and "Real-World Data/Evidence Optimization for Clinical R&D" respectively, which shared practical experiences of Elixir Clinical Research in real-world studies.

Strong Collaboration

01

Breaking news | Elixir Clinical Research partners with Cancer Hospital Chinese Academy of Medical Sciences to set regional standards for clinical data on malignancies in Beijing, which adds new momentum to high-quality clinical trials

Elixir Clinical Research Co., Ltd. was invited by Cancer Hospital Chinese Academy of Medical Sciences to be one of expert group members to complete jointly the general part of Data Collection Standards for Clinical Research in Malignancies. The data standard will serve as a local standard for clinical research data on malignancies, and provide complete high-quality real-world data specifications and standards. Elixir Clinical Research will support the Cancer Hospital Chinese Academy of Medical Sciences in the preparation of collection standards, terminology standards, coding, metadata sets, etc.

02

Yuanxin Technology and Elixir Clinical Research entered into a strategic partnership to focus on innovation and empower real-world studies

On April 6, 2022, Yuanxin Technology and Elixir Clinical Research announced a formal strategic cooperation agreement between the two companies. According to the agreement, both parties will carry out in-depth cooperation in such fields as real-world studies. Both parties will give full play to their respective strengths to provide multi-dimensional high-value data analysis support for clinical research and decision support for medical institutions and pharmaceutical companies through the integration of pharmaceutical services supply chain capabilities and real-world studies, which will further enrich clinical research tools, improve decision making, accelerate the process of new drug development and results translation, and help the industry achieve high-quality development.

Professional Honors

Good News - Elixir Clinical Research won the Hero Award - the Most Innovative CRO Company in Science and Technology in 2022

On June 29, the 2022 (3rd) Brand Innovation Development Conference (BIDC) under the theme of "New Dynamic, New Vigor, New Development" was successfully held online and concluded in Beijing. As a technology-enabled full service clinical CRO, Elixir Clinical Research received the "Hero Award - the Most Innovative CRO Company in Science and Technology in 2022" because of its strong commitment and innovation in the field of digital clinical research, and its outstanding performance in using big data, artificial intelligence and other related technologies to empower all phases of clinical trials.

Future

Elixir Clinical Research

Follows its original intentions with professionalism

Responds to every expectation

Forges excellence in quality

Its future will be better than the past like fireworks into the sky

A fresh start in the second half of 2022

Elixir Clinical Research